Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
SBTX Silverback Therapeutics	$14.03 -3.4%	$16.83	$2.80 ▼ $8.97	$505.89M	0.6	337,931 shs	1.67 million shs
STML Stemline Therapeutics	$11.83	$11.83	$3.21 ▼ $18.22	$621.21M	1.78	1.52 million shs	1,084 shs
ZYME Zymeworks	$13.93 -0.8%	$13.10	$9.03 ▼ $17.70	$1.05B	1.26	532,640 shs	195,743 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.73%
SBTX Silverback Therapeutics	0.00%	-16.97%	-18.92%	+1.89%	+9.00%
STML Stemline Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ZYME Zymeworks	-2.16%	+12.94%	-1.40%	+13.03%	+34.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STML Stemline Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	2.3379 of 5 stars	3.5	0.0	0.0	0.0	2.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A
STML Stemline Therapeutics	0.00	N/A	N/A	N/A
ZYME Zymeworks	2.90	Moderate Buy	$21.43	53.82% Upside

Current Analyst Ratings Breakdown

Latest STML, CALT, ZYME, and SBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
5/20/2025	ZYME Zymeworks	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/20/2025	ZYME Zymeworks	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A
STML Stemline Therapeutics	$43.22M	14.37	N/A	N/A	$3.26 per share	3.63
ZYME Zymeworks	$122.87M	8.52	N/A	N/A	$6.63 per share	2.10

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	∞	N/A	N/A	-29.62%	-28.20%	N/A
STML Stemline Therapeutics	-$76.82M	-$1.83	N/A	N/A	N/A	-150.30%	-48.14%	-41.35%	N/A
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest STML, CALT, ZYME, and SBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A
STML Stemline Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
SBTX Silverback Therapeutics	N/A	67.87	67.87
STML Stemline Therapeutics	N/A	7.43	7.37
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
SBTX Silverback Therapeutics	74.89%
STML Stemline Therapeutics	75.80%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
SBTX Silverback Therapeutics	34.40%
STML Stemline Therapeutics	11.20%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable
STML Stemline Therapeutics	92	52.51 million	N/A	Optionable
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

STML, CALT, ZYME, and SBTX Headlines

Recent News About These Companies

Zymeworks Reports Q2 Results and FDA Clearance

August 19 at 9:47 AM | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital Ltd

August 17 at 6:45 AM | marketbeat.com

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13, 2025 | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12, 2025 | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | marketbeat.com

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | americanbankingnews.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11, 2025 | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11, 2025 | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11, 2025 | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Rating of "Moderate Buy" by Analysts

August 10, 2025 | americanbankingnews.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STML, CALT, ZYME, and SBTX Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/18/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Silverback Therapeutics NASDAQ:SBTX

$14.03 -0.50 (-3.44%)

As of 08/18/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stemline Therapeutics NASDAQ:STML

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Zymeworks NYSE:ZYME

$13.93 -0.12 (-0.85%)

As of 03:18 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time